Therapeutic Insights
Filter News
Found 969 articles
-
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
1/31/2023
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st December 2022 (Q2 FY23).
-
Aluna Raises $15.3M in Series B Funding To Empower Asthma, COPD and Cystic Fibrosis Patients and Their Doctors
1/31/2023
Aluna, the award-winning lung health management platform, announced it has completed a $15.3 million Series B round of financing to continue growing its solution among doctors and patients managing asthma, cystic fibrosis and COPD.
-
Phase I/II data showed AC Immune’s anti-amyloid-beta vaccine candidate could safely elicit an antibody response in patients with Alzheimer’s disease. Now, it will expand to Down Syndrome patients.
-
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
1/26/2023
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the first interim safety, tolerability and immunogenicity findings from the Phase 1b/2 ABATE trial of its anti-amyloid-beta (Abeta) vaccine ACI-24.060 in patients with prodromal Alzheimer’s disease (AD).
-
Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)
1/26/2023
Coya Therapeutics, Inc. announced the recent publication of an article entitled “Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s Disease” in the peer reviewed journal Acta Neuropathologica Communications.
-
OstoBuddy and South Asian IBD Alliance Named Winners of Innovation Challenge, in Collaboration with Bristol Myers Squibb, to Address Unmet Needs in Inflammatory Bowel Disease
1/26/2023
Lyfebulb is pleased to announce the winners for the Innovation Challenge "Addressing Unmet Needs in IBD" in collaboration with Bristol Myers Squibb.
-
Alzamend Neuro to Present at Sequire Biotechnology Conference
1/26/2023
Alzamend Neuro, Inc. today announced that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2, 2023.
-
Cassava Sciences reported Phase II data from its Alzheimer's candidate simufilam Tuesday. The company’s stock dropped 17% following the reveal.
-
Research hasn't shown that removing amyloid plaques alone improves function in Alzheimer's patients, said Sharon L. Rogers, CEO of AmyriAD.
-
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
1/24/2023
Galectin Therapeutics Inc. announced that the scientific paper, “Machine Learning Liver Histology Scores Correlate With Portal Hypertension Assessments In Nonalcoholic Steatohepatitis Cirrhosis,” was published in Alimentary Pharmacology and Therapeutics, a prominent peer-reviewed gastroenterology journal.
-
The FDA issued a complete response letter Thursday refusing accelerated approval for Eli Lilly’s Alzheimer’s disease candidate donanemab.
-
The neurodegenerative drug development space saw incremental victories in 2022. Leaders from Eisai, Voyager and QurAlis discuss upcoming milestones.
-
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
1/18/2023
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its collaboration partner, Life Molecular Imaging (LMI), has imaged the first patient in ADvance, the pivotal Phase 3 trial of PI-2620, a Tau PET (positron emission tomography) imaging agent for AD (Alzheimer’s disease).
-
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
1/18/2023
Krystal Biotech, Inc. announced today that the European Commission has granted orphan designation for KB407 for the treatment of Cystic Fibrosis (CF).
-
APRINOIA Therapeutics and ROSS Acquisition Corp II Announce Business Combination Agreement to Create Publicly Listed Company Focused on Neurodegenerative Diseases
1/18/2023
APRINOIA Therapeutics Inc. and Progressive Supranuclear Palsy ("PSP"), and Ross Acquisition Corp II today announced that they have entered into a definitive agreement (the "Business Combination Agreement") for a business combination (the "Business Combination").
-
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
1/16/2023
Eisai Co., Ltd. and Biogen Inc. announced that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril1 antibody for the treatment of mild cognitive impairment due to Alzheimer's disease and mild AD dementia with confirmed presence of amyloid pathology in the brain to the Pharmaceuticals and Medical Devices Agency.
-
BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in Japan
1/16/2023
BioArctic AB's partner Eisai announced that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril[1] antibody for the treatment of mild cognitive impairment due to Alzheimer's disease and mild AD dementia with confirmed presence of amyloid pathology in the brain to the Pharmaceuticals and Medical Devices Agency.
-
BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in the EU
1/11/2023
BioArctic AB's partner Eisai announced that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer's disease and mild AD dementia) to the European Medicines Agency.
-
AlzeCure Selects CD and Enters Next Development Phase with Alzstatin ACD680 Against Alzheimer's
1/11/2023
AlzeCure Pharma AB announced that the company has chosen a candidate drug and started the preclinical development phase with the company's preventive and disease-modifying candidate drug Alzstatin® ACD680.
-
Early, Accurate Diagnosis of Alzheimer’s Disease with DISCERN™ Test is Critical for Identifying Appropriate Patients for Prescribing and Coverage of LEQEMBI™
1/10/2023
SYNAPS Dx, a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease, emphasizes that FDA approval of LEQEMBI™ as a new drug for AD signals a turning point for clinicians, payers and all stakeholders in the benefits community.